| Species |
Human |
| Protein Construction |
tPA [Ser36-Pro562, which consists of two chains: chain A (Ser36-Arg310) and chain B (Ile311-Pro562)]
Accession # P00750-1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its ability to cleave a peptide substrate, NcarbobenzyloxyGlyGlyArg7amido4methylcoumarin (ZGGRAMC). The specific activity is > 200 pmol/min/μg. Test result meets the standard. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
60.13 kDa |
| Apparent Molecular Weight |
It migrates to 40-45 kDa (Chain A) and 35-40 kDa (Chain B) based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in 20mM MES, 300mM Nacl, 200mM Arginine (pH 5.5). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in 20mM MES, 300mM Nacl, 200mM Arginine (pH 5.5). |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Tissue plasminogen activator (tPA) is the predominant plasminogen activator present in the vascular and nervous systems.t tPA is not only neuroprotective for postnatal primary cortical neurons, but also that the predominant route for enhancing cell survival is via an mTORdependent mechanism. |
| Synonyms |
t-PA; tPA; Alteplase; Reteplase; PLAT; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
